You just read:

PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress

News provided by

PharmaMar

Oct 10, 2016, 09:00 ET